Johnson & Johnson (JNJ) Financials
PeriodQ2 FY2026
Published
Johnson & Johnson reported $25.31 billion in sales for Q2 FY2026, the quarter ended June 28, 2026, up 6.6% from $23.74 billion a year earlier and a quarterly sales record for the company. Net income was $5.53 billion, essentially unchanged from $5.54 billion, and diluted EPS was $2.27 against $2.29, with the sales growth absorbed by a higher effective tax rate, a new supply chain restructuring program and costs of the planned Orthopaedics separation. Innovative Medicine sales of $16.38 billion drove the quarter as the oncology franchise led by DARZALEX, together with TREMFYA in immunology, more than covered continued STELARA biosimilar erosion, while MedTech contributed $8.93 billion.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $25,310,000,000 | up 6.6% |
| Net income | $5,534,000,000 | down 0.1% |
| Diluted EPS | $2.27 | down 0.9% |
| Innovative Medicine sales | $16,384,000,000 | up 7.8% |
| MedTech sales | $8,926,000,000 | up 4.5% |
Company details
| Name | Johnson & Johnson |
|---|---|
| Ticker | JNJ |
| CIK | 0000200406 |
| Exchange | NYSE |
| State | New Jersey |
| Incorporation | New Jersey |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
| Latest period covered | Q2 FY2026, ended 2026-06-28, 10-Q, accession 0000200406-26-000153 |
| Fiscal year end | 01/03 (MM/DD) |
| Next expected filing | 10-Q around 2026-10-21 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Johnson & Johnson Q2 FY2026
How much revenue did Johnson & Johnson report in Q2 FY2026?
Johnson & Johnson reported $25.31 billion in sales for Q2 FY2026, the quarter ended June 28, 2026. That is up 6.6% from $23.74 billion in the same quarter a year earlier, and a quarterly sales record for the company.
What were Johnson & Johnson's earnings and EPS in Q2 FY2026?
Johnson & Johnson earned $5.53 billion in Q2 FY2026, down 0.1% from $5.54 billion a year earlier, with diluted EPS of $2.27 against $2.29. Earnings were flat on higher sales because the effective tax rate rose and the quarter carried a new supply chain restructuring charge, Orthopaedics separation costs and higher litigation expense.
How did Johnson & Johnson's Innovative Medicine and MedTech segments perform in Q2 FY2026?
Innovative Medicine sold $16.38 billion to customers in Q2 FY2026, up 7.8% from $15.20 billion, and MedTech sold $8.93 billion, up 4.5% from $8.54 billion. Innovative Medicine remains the larger of Johnson & Johnson's two segments, where oncology growth and TREMFYA's expansion in immunology outweighed the continuing STELARA biosimilar decline.
Why did Johnson & Johnson's profit not grow with sales in Q2 FY2026?
Johnson & Johnson's sales reached $25.31 billion in Q2 FY2026, up 6.6% from a year earlier, while net income of $5.53 billion was little changed from $5.54 billion. The quarter carried a higher effective tax rate than a year earlier, a newly initiated supply chain restructuring program, costs of the planned Orthopaedics separation and higher litigation expense.
Where can I get Johnson & Johnson (JNJ) financial data in machine-readable form?
Ticker Scout publishes Johnson & Johnson's financial statements as JSON at https://tickerscout.ai/jnj/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/jnj/narrative.md and https://tickerscout.ai/jnj/events.md. Johnson & Johnson's SEC CIK is 0000200406. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Johnson & Johnson (JNJ) next file with the SEC?
Johnson & Johnson (JNJ) is expected to file its next Form 10-Q with the SEC on or around October 21, 2026. That date is a projection rather than a company-announced date: it is derived from Johnson & Johnson's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-28, SEC accession 0000200406-26-000153.
Related companies
How this page was built
This page was built from Johnson & Johnson's own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names six such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.